ALTIMMUNE, INC. Long-Term Debt, Maturity, Year Two
ALTIMMUNE, INC. (ALT) had Long-Term Debt, Maturity, Year Two of $21.61 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-08-12
- 2026-06-30: Long-Term Debt, Maturity, Year Two $21.61M.
- 2026-03-31: Long-Term Debt, Maturity, Year Two $21.61M.
- 2025-12-31: Long-Term Debt, Maturity, Year Two $1.71M.
- 2014-09-30: Long-Term Debt, Maturity, Year Two $750.01K.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2026-06-30 | $21.61M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $21.61M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.71M 10-K · filed 2026-03-06 |
| 2014-09-30 | $750.01K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $750.01K 10-Q · filed 2014-08-05 |
| 2014-03-31 | $750.01K 10-Q · filed 2014-05-08 |
| 2013-09-30 | $1000.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $1000.00K 10-Q · filed 2013-08-08 |
| 2012-09-30 | $909.10K 10-Q · filed 2012-11-06 |
| 2012-06-30 | $909.10K 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |